BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Aug. 17, 2006--Akorn, Inc. (AMEX:AKN) today announced that it has submitted the first Abbreviated New Drug Application (ANDA) with the Office of Generic Drugs on behalf of FDC Limited (FDC). Akorn and FDC announced the signing of a purchase and supply agreement in July 2004. FDC is India’s second largest manufacturer and marketer of ophthalmic pharmaceutical products. The proposed drug product is an ophthalmic solution that will be manufactured by FDC in a blow-fill-seal container closure system.
